Related Experiment Videos
[Glucocorticoid therapy in Duchenne muscular dystrophy]
1Department of neurology, Toneyama National Hospital.
Rinsho Shinkeigaku = Clinical Neurology
|December 1, 1996
Summary
Glucocorticoids may slow Duchenne muscular dystrophy (DMD) progression for up to three years, but benefits diminish over time. Further research is needed for optimal dosing and reduced side effects.
Area of Science:
- Neurology
- Pharmacology
- Genetics
Background:
- Early studies suggested potential benefits of glucocorticoids for Duchenne muscular dystrophy (DMD).
- Conflicting results from early trials necessitated further investigation into glucocorticoid efficacy.
- Prednisone trials in 1987 showed promise in slowing muscle strength decline.
Purpose of the Study:
- To investigate the effects of glucocorticoid therapy in Duchenne muscular dystrophy patients.
- To assess the long-term efficacy and benefits of prednisolone treatment in DMD.
Main Methods:
- A trial involving 10 DMD patients treated with prednisolone (1 mg/kg) on alternate days.
- Monitoring of daily living activities and treatment effects over 192 weeks.
- Review of existing short-term, randomized, double-blind, controlled trials on glucocorticoids in DMD.
Main Results:
- Seven out of 10 patients maintained daily living activities at 48 weeks.
- Benefits of prednisolone treatment did not persist beyond 192 weeks in any patient.
- Glucocorticoids demonstrated a significant slowing of disease progression for at least three years.
Conclusions:
- Glucocorticoid therapy, specifically prednisolone, offers a valuable, albeit temporary, treatment option for Duchenne muscular dystrophy.
- Benefits of glucocorticoids in DMD must be carefully weighed against potential side effects.
- Further research is required to optimize treatment schedules and develop safer alternatives for DMD.